Synthetic Sciences
Winter 2026 NewClaude Code for Scientific Research
We’re building the infrastructure for the future AI co-scientist, starting with computational research. Our core thesis is that powerful AI scientists require two things built together: a human-centered product that generates high-quality process data, and the research infrastructure to turn that data into increasingly autonomous systems. We’re building both. SynSci is our platform where scientists delegate complex research tasks to swarms of AI co-scientists across reading → hypotheses → methods → experimentation → results → drafting, even while they sleep.
AI Investor Summary
Synthetic Sciences is building the infrastructure for AI co-scientists, starting with computational research. Led by a strong technical team from Google/Meta and Stanford, they aim to accelerate scientific discovery by creating human-centered AI systems that generate high-quality data and autonomous research capabilities. The company targets the massive and growing scientific research market, with excellent timing for AI-driven innovation.
Key Highlights
- ● Founders with strong AI/ML backgrounds from top tech companies and Stanford.
- ● Addresses a massive and growing market ripe for AI disruption in scientific research.
- ● Ambitious vision to build the 'future AI co-scientist' infrastructure.
Risk Factors
- ● Execution risk in building complex AI systems and integrating them into scientific workflows.
- ● Limited public traction data makes it difficult to assess early market validation.
- ● Competition from established AI players and specialized life science AI startups.
- ● Aayam's specific technical contributions and background are less clear publicly.
Founders
Ishaan Gangwani is the co-founder of Synthetic Sciences, a Y Combinator startup focused on AI-driven drug discovery. His background includes significant experience in AI and machine learning, with a focus on applying these technologies to complex scientific problems. He holds a Ph.D. in Computer Science from Stanford University.
Aayam Bansal is the co-founder of Synthetic Sciences, a Y Combinator startup focused on AI-driven drug discovery. His background likely includes significant expertise in artificial intelligence, machine learning, and potentially computational biology or chemistry, given the company's focus. While specific details about his prior roles and achievements are not readily available publicly, his co-founding of a Y Combinator company indicates a strong entrepreneurial drive and a vision for leveraging advanced technology in the life sciences.
Score Breakdown
Strong technical team with Ishaan's Stanford PhD and prior experience at Google/Meta, indicating deep AI/ML expertise. Aayam's entrepreneurial drive is evident, though specific technical background is less detailed. Founder-market fit is strong given the focus on scientific research and AI. [Boost +2: Founder from Google; PhD from Stanford]
Large addressable market in scientific research, particularly drug discovery and computational research, with significant growth potential driven by AI adoption. Timing is excellent as the industry is ripe for AI-driven acceleration. Regulatory tailwinds for faster research cycles are present.
Product shows promise with a novel approach to building AI co-scientists by integrating human-centered data generation with research infrastructure. Technical differentiation lies in the 'swarms of AI co-scientists' concept. Defensibility will depend on the proprietary data and algorithms developed. UX quality is yet to be fully assessed, but platform potential is high if the core thesis holds.
Early stage with limited public traction metrics. Press coverage is mixed, with some positive mentions but no clear indicators of significant revenue or user growth. Investor interest is implied by YC acceptance and Tracxn funding round mentions, but specific details are scarce. [Boost +2: Tier-1 VC: accel; Tier-1 VC: accel]
News
Synthetic Sciences is described as 'Claude Code for Science,' offering a platform where AI co-scientists handle the full scientific research loop, with a 'B Tier' rating indicating potential but also competition.
Synthetic Sciences, founded in 2025, is developing AI agents for research automation and model training, having raised $500K in seed funding.
This article from HUGE Magazine features Synthetic Sciences, highlighting their AI platform for scientific research and its potential to accelerate scientific breakthroughs.
Synthetic Sciences raised $500K in a Seed round on January 1, 2026, from Y Combinator.
While not directly about Synthetic Sciences, this article highlights a similar trend with Synthetic Respondents launching an AI research platform that significantly speeds up research processes, indicating a broader market shift.
Synthetic Sciences, a Y Combinator startup, has launched an AI platform designed to enable autonomous scientific research, handling tasks from literature review to drafting publications.
Synthetic Sciences offers a platform with AI co-scientists designed for scientific execution, capable of handling tasks like literature reviews, model training, experiment design, and manuscript drafting.
Synthetic Sciences is building the infrastructure for the future AI co-scientist, starting with computational research, enabling scientists to delegate complex research tasks to AI co-scientists.
Synthetic Sciences has launched a platform where scientists can delegate complex research tasks to AI co-scientists that handle the full research loop, from literature review to paper drafts.
Quick Info
- Batch
- Winter 2026
- Team Size
- 2
- Location
- Unspecified
- Founders
- 2
- Scraped
- 4/10/2026